Local Resection of Primary Tumor in Upfront Stage IV Breast Cancer

Thomas Kolben\textsuperscript{a}  Theresa M. Kolben\textsuperscript{a}  Isabelle Himsl\textsuperscript{b}  Tom Degenhardt\textsuperscript{a}  Jutta Engel\textsuperscript{c}
Rachel Wuerstlein\textsuperscript{a}  Sven Mahner\textsuperscript{a}  Nadia Harbeck\textsuperscript{a}  Steffen Kahlert\textsuperscript{a}

\textsuperscript{a}Breast Center, Department for Obstetrics and Gynecology and Comprehensive Cancer Center of LMU, University Hospital Munich – Grosshadern, Ludwig-Maximilian University, Munich, Germany; \textsuperscript{b}Klinikum Dritter Orden, Department for Obstetrics and Gynecology, Munich, Germany; \textsuperscript{c}Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Department of Medical Informatics, Biometry and Epidemiology (IBE), Ludwig-Maximilian University, Munich, Germany

Introduction

In the United States and Western Europe, approximately 5% of breast cancer (BC) patients present with stage IV at their primary diagnosis [1]. Stage IV BC is defined as BC that has metastasized to distant organs. The standard therapeutic approach is palliative; systemic therapy is considered the mainstay of treatment [2, 3]. Local resection of the primary tumor is recommended for symptom control, e.g. for ulceration and bleeding or alleviation of pain. A substantial survival benefit due to resection of the primary tumor is not expected for stage IV BC. The development of new systemic therapy regimens and new agents has led to a significant increase in the overall survival (OS) of patients suffering from metastatic disease [4]. With this gain in survival time, the risk of local progression and associated problems also increases, which justifies considering local resection as part of the initial treatment approach.

Additionally, several retrospective studies reported an association of local resection with increased survival time [5, 6]. It has been assumed that a decrease of circulating tumor cells (CTCs) by surgical reduction of the total tumor volume (including tumor stem cells as a source of CTCs) decreases the rate of new metastasis and is therefore associated with a better prognosis [7]. Another reason for longer survival after resection of the primary tumor might be an activation of autoimmunity and an increase in drug efficacy [8].

With the availability of more sensitive imaging modalities such as positron emission tomography/computed tomography (PET/CT), the profile of metastatic breast cancer (MBC) has changed. Patients with metastatic disease can be diagnosed earlier, which confronts us with a new group of patients with ‘low tumor burden’. These patients might be good candidates for local resection.
To our knowledge, up to now, final results from only 2 prospective studies are available focusing on the question whether local therapy of the primary tumor in stage IV BC has an effect on the prognosis and survival of such patients [9, 10]. A number of promising randomized trials investigating this topic are underway (still recruiting or in follow-up), summarized by Shien [11].

The purpose of our study was to identify the potential impact of surgical therapy of the primary tumor in patients with primary stage IV BC.

**Patients and Methods**

Between 1990 and 2006, 236 patients with primary MBC treated at the University Hospital Munich Grosshadern were included in this retrospective analy-
In the univariate model, patients with surgical therapy of the primary breast tumor had significantly prolonged median OS of 28.9 (22.2–35.7) vs. 23.9 (19.3–28.5) months (p = 0.015) (fig. 1).

The association of local treatment with OS compared to no local surgery was not homogenous across all subgroups. In more advanced disease groups, local treatment was not associated with a significant OS prolongation. Local surgery did not show any significant effect on survival outcome in patients with involvement of 2 organ systems (16.3 (10.3–22.4) vs. 39.2 (23.2–55.2) months; not significant), 3 organ systems (22.1 (13.9–30.3) vs. 15.0 (7.2–38.0) months; not significant), and more than 3 organ systems (9.8 (0.5–19.2) vs. 2.8 (0.0–22.5) months; not significant). However, patients with MBC limited to 1 organ system had significant prolongation of OS after local surgery (39.3 (31.4–47.3) vs. 24.9 (16.6–33.3) months; p = 0.012) (fig. 2).

Patients with metastases limited to 1 visceral organ or 1 soft tissue system, presented with prolonged OS in the surgery group (27.3 (17.4–37.2) vs. 13.4 (0–29.8) months; p = 0.042). A considerable prolongation of OS was also observed in patients with bone metastases only (43.3 (33.3–53.3) vs. 24.9 (16.6–33.3) months; p = 0.115) (fig. 3).

Patients with metastases to multiple organ systems (19.0 (10.6–27.4) vs. 25.9 (14.1–37.7) months; not significant) or any CNS involvement (2.1 (0–6.5) vs. 2.8 (2.7–2.8) months; not significant) had no significant improvement in survival after surgery (fig. 3).

Patients who were asymptomatic at presentation had a significantly higher increase in OS after surgery (37.5 (23.8–51.2) vs. 15.0 (11.5–18.6) months; p = 0.029) compared to symptomatic patients (24.7 (17.3–32.2) vs. 23.9 (19.3–28.5) months; not significant).

In the multivariate analysis, patients with hormone receptor-negative BC were significantly more likely to have shorter survival (relative risk (RR) 1.6; p = 0.004). The RR of dying increased with an increasing number of involved organ systems (p < 0.001). The risk for shorter survival was significantly higher in patients presenting with symptoms at diagnosis (p < 0.001) (table 2).
The exploratory analysis of particular groups revealed surgery not to be associated with a homogenous effect on survival across the subgroups. In general, cases with a lower tumor load (e.g., less involved organ systems or asymptomatic disease) had a higher benefit from surgery. The test for interaction was significant for number of involved organ systems, location, and symptoms (fig. 4).

A landmark analysis limiting the presented data to only patients who survived for more than 6 months revealed similar results. Pa-

<table>
<thead>
<tr>
<th>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</td>
</tr>
</tbody>
</table>

Table 2. Multivariate analysis

<table>
<thead>
<tr>
<th>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</td>
</tr>
</tbody>
</table>

Table 2. Multivariate analysis

<table>
<thead>
<tr>
<th>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</td>
</tr>
</tbody>
</table>

Table 2. Multivariate analysis

<table>
<thead>
<tr>
<th>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</td>
</tr>
</tbody>
</table>

Table 2. Multivariate analysis

<table>
<thead>
<tr>
<th>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</td>
</tr>
</tbody>
</table>

Table 2. Multivariate analysis

<table>
<thead>
<tr>
<th>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</td>
</tr>
</tbody>
</table>

Table 2. Multivariate analysis

<table>
<thead>
<tr>
<th>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</td>
</tr>
</tbody>
</table>

Table 2. Multivariate analysis

<table>
<thead>
<tr>
<th>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment (non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal status, type of systemic treatment). RR = Relative risk; CI = confidence interval; HR = hormone receptor.</td>
</tr>
</tbody>
</table>
patients with bone metastasis only, metastases limited to 1 organ system, or asymptomatic disease had a considerably better prognosis in the surgery group, whereas all other groups showed no association with an effect of surgery (data not shown).

**Discussion**

In the univariate analysis, those patients with metastatic disease who had the primary tumor surgically removed showed significantly improved OS, which is consistent with other studies [5, 6, 12].

Different hypotheses exist to explain this positive effect of local surgery in the advanced stage of the disease. However, the true mechanism remains unclear. Removal of the primary tumor and thereby reduction in the total tumor burden is supposed to be associated with reduced tumor-induced immunosuppression [8] and decreased self-seeding of the primary tumor to distant sites [13], which again could be due to a reduction in CTCs [14]. Associated removal of BC stem cells, which can be the source of chemo-resistant clones, could influence outcome in a positive way by making metastases more sensitive to chemotherapeutic regimens [15].

The benefit of local surgery in MBC patients is not supported by results of a prospective randomized controlled trial conducted in India with 350 patients. This cohort received initial treatment with 6 cycles of anthracycline-based chemotherapy or endocrine therapy, and only patients who responded well to chemotherapy were enrolled in the study. Surgery did not extend survival in this trial. After 2 years, 41.9% of those who underwent breast surgery followed by radiotherapy were alive compared to 43.0% of women who received no local therapy [9]. The exclusion of non-responders to chemotherapy is in contrast to our study which did not exclude patients with a poor prognosis or low response to systemic treatment.

The prospective Indian trial focused on patients with a higher risk profile, while in our retrospective study the number of patients with low-risk metastases was substantially higher.

Consistent with the Indian randomized trial, we were unable to observe any substantial benefit from surgery in patients with high-risk metastases (limiting the analysis to patients who did not survive the first 6 months after diagnosis). Focusing on the low-risk patients, however, we could see a survival benefit in the surgery group in all univariate-analyzed subgroups (in patients with a documented survival of more than 6 months). However, in our multivariate model, no effect of local surgery was seen.
Regarding the inclusion criteria for patients, our study is more comparable to another prospective randomized study conducted in Turkey [10]. In this study, the survival rate after 40 months of median follow-up was significantly higher in the surgery group (46 vs. 37 months). The treatment algorithm differed between the 2 prospective studies. In contrast to the Indian study, all the Turkish women assigned to locoregional therapy received systemic therapy after breast-conserving surgery and breast irradiation – not before. Furthermore, patients with HER2-positive tumors were treated with trastuzumab.

In our analysis, the majority of patients who were treated surgically received systemic therapy after the surgery (71%). Pre- or postoperative systemic treatment did not result in significantly different outcome.

Besides the survival benefit found in the total cohort after local surgery, the Turkish investigators, similar to us, also identified subgroups who had a significant benefit from local surgery, i.e. patients with less aggressive tumor biology and patients with metastases limited solely to the bone [10].

This is strikingly similar to our univariate findings. We also observed a significant prolongation of survival in patients with disease limited to the bone in the surgery group.

In a review focusing on surgery in metastatic patients, Hartmann et al. [16] state that based on current data, locoregional treatment in primary MBC should not be routinely recommended in patients with asymptomatic primary tumors. In contrast, our data suggest that survival was longer especially in asymptomatic patients of the surgery group.

Patients with involvement of only 1 organ system were treated more often with surgery of the primary tumor, which is consistent with the findings of a meta-analysis of 10 studies including almost 29,000 patients with MBC [17].

Yet, in our analysis, the decision for local treatment was biased by the extent and presentation of the metastatic disease. Patients with more advanced MBC seemed to not benefit from removal of the primary tumor. A reason for this could be that a reduction in total tumor burden loses its effect once a certain tumor load is reached.

There are some limitations to our analysis: One obvious limitation is the retrospective and monocentric design. The selection of patients for local therapy was confounded by a more favorable presentation in the local surgery group in patients with oligometastatic disease, i.e. patients with less aggressive tumor biology and patients with metastases limited solely to the bone [10].

We identified a subgroup of patients with oligometastatic disease to the bone and limited metastatic disease burden who might benefit from local therapy. The results were almost identical.

A possible strength of our analysis is the substantial follow-up and patient numbers. However, the latter still seems too small to confirm an effect of local surgery in the multivariate model.

A current review supports the potential OS benefit we observed in the local surgery group in patients with oligometastatic disease, especially if limited to the bone [18].

The treatment of MBC will always be a multimodal approach influenced by the patient’s age and comorbidities as well as specific tumor characteristics.

Despite the enormous problem of bias in a retrospective trial, especially in the complex situation of MBC, our univariate data were similar to those of the 2 randomized trials published so far [9, 19].

According to our analysis, asymptomatic patients and those with only 1 involved organ system (especially bone only) could be considered low-risk, while patients with symptomatic disease or more than 1 involved organ system or CNS metastases should be considered high-risk.

Essentially, surgery of the primary tumor should only be offered to metastatic high-risk patients if local control seems helpful in the context of palliative treatment. In contrast, for patients with low-risk metastases, surgery could potentially provide a small but significant survival benefit and could be offered more liberally.

Patients with oligometastatic disease to the bone and limited metastatic disease burden might be potential candidates for local surgery in that situation.

However, since local surgery lacked significance in the multivariate model, we suggest to investigate this topic with larger patient numbers.

Acknowledgement

The authors thank the Department of Pathology, University Hospital Munich, Ludwig Maximilian University Munich, Germany for providing the historical data for this analysis.

Disclosure Statement

MS received research support, advisory board fees, honoraria, and travel support from AstraZeneca, Bayer, Boehringer Ingelheim, Jenapharm, GSK, JanssenCilag, Medac, MSD, Pharmamar, Roche, Tesaro, and Teva. All other authors declare no conflict of interest.

References


